Peer-reviewed veterinary case report
Safety of autologous cancer vaccine in cats with tumors 2015-2020
By Lucroy, Michael D et al.·Published in Journal of feline medicine and surgery·2022·Torigen Pharmaceuticals, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Field safety experience with an autologous cancer vaccine in tumor-bearing cats: a retrospective study of 117 cases (2015-2020).
- Species:
- cat
Plain-English summary
A group of 117 cats with solid tumors received an autologous cancer vaccine, which is a type of treatment made from their own cancer cells. Most cats experienced very few side effects, with only 6 cats reporting mild reactions that went away on their own without needing extra treatment. This suggests that the cancer vaccine is generally safe for cats and could be a good option for pet owners worried about the side effects of traditional cancer treatments like chemotherapy or radiation. More research is needed to see how effective this vaccine is in treating cancer in cats.
People also search for: cat cancer vaccine side effects · autologous cancer treatment for cats · cat tumor treatment options
Abstract
OBJECTIVES: The aim of this study was to determine the frequency and severity of adverse events (AEs) reported from use of an adjuvanted whole-cell autologous cancer vaccine in cats with solid tumors under field conditions. METHODS: The case accession database at Torigen Pharmaceuticals was searched to identify client-owned cats that underwent biopsy or surgical resection of their primary tumor, had histologic confirmation of neoplasia and received at least one subcutaneous dose of an adjuvanted whole-cell autologous cancer vaccine. Records were reviewed for any reported AEs. RESULTS: In total, 117 cats met the inclusion criteria and received 422 doses of autologous cancer vaccine. Six (5.1%) cats had seven reported AEs, with the majority of these (85.7%) being characterized as grade 1 or 2 (mild) and resolving without medical intervention. CONCLUSIONS AND RELEVANCE: AEs were infrequent in cats treated with an adjuvanted whole-cell autologous cancer vaccine under typical field use conditions. This form of active cancer immunotherapy appears to be well tolerated by cats and may represent a treatment option for owners who are concerned about AEs associated with chemotherapy or radiotherapy. Additional studies are warranted to determine the efficacy of this form of individualized immunotherapy in cats with solid tumors.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34328359/